Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak Growth Hormone (GH) release following short-term low-dose GH administration in young healthy adults

Kevin Yuen, Jan Frystyk, Margot Umpleby, Linda Fryklund, David Dunger

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

High-dose GH administration is commonly associated with impaired insulin sensitivity (SI) in humans. Paradoxically we have shown that low-dose GH (1.7 μg/kg·d) administration enhances β-cell function in young healthy adults. In the present double-blind, placebo-controlled, cross-over study, we explored the physiological effects of this low GH dose on glucose metabolism in 12 young healthy adults (seven males, 19-29 yr). At pretreatment and after each 14-d treatment block, overnight metabolic profiles were assessed followed by a hyperinsulinemic euglycemic clamp, whereas fasting blood samples were collected weekly. In subjects treated with GH first (group A, n = 6), GH treatment increased total IGF-I (P <0.05) and IGF binding protein-3 (P <0.01) after 7 d, but these levels subsequently returned to pretreatment levels after 14 d. In contrast, free IGF-I increased (P <0.05), and overnight GH pulse peak amplitude decreased (P <0.01) after 14 d. In subjects treated with placebo first (group B, n = 6), all biochemical parameters were unchanged after placebo treatment, whereas the changes in free and total IGF-I were similar to those of group A after GH treatment. Combined clamp data from both groups A and B (n = 12) showed that 14-d GII treatment decreased overnight plasma insulin levels (P <0.02) and hepatic glucose appearance (P <0.05) and increased SI (P <0.01). Of note, the GH-induced changes in SI positively correlated with the changes in free IGF-I (r = 0.72, P <0.01). In conclusion, low-dose GH administration enhanced S I and suppressed endogenous peak GH release, and we hypothesize that these effects are the direct result of increased serum levels of free IGF-I.

Original languageEnglish (US)
Pages (from-to)3956-3964
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Growth Hormone
Insulin Resistance
Young Adult
Insulin
Placebos
Clamping devices
Therapeutics
Glucose
Insulin-Like Growth Factor Binding Protein 3
Glucose Clamp Technique
Metabolome
Metabolism
Cross-Over Studies
Fasting
Blood
Plasmas
Liver
Serum

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{adf0870374a64bc2932cb737c497781c,
title = "Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak Growth Hormone (GH) release following short-term low-dose GH administration in young healthy adults",
abstract = "High-dose GH administration is commonly associated with impaired insulin sensitivity (SI) in humans. Paradoxically we have shown that low-dose GH (1.7 μg/kg·d) administration enhances β-cell function in young healthy adults. In the present double-blind, placebo-controlled, cross-over study, we explored the physiological effects of this low GH dose on glucose metabolism in 12 young healthy adults (seven males, 19-29 yr). At pretreatment and after each 14-d treatment block, overnight metabolic profiles were assessed followed by a hyperinsulinemic euglycemic clamp, whereas fasting blood samples were collected weekly. In subjects treated with GH first (group A, n = 6), GH treatment increased total IGF-I (P <0.05) and IGF binding protein-3 (P <0.01) after 7 d, but these levels subsequently returned to pretreatment levels after 14 d. In contrast, free IGF-I increased (P <0.05), and overnight GH pulse peak amplitude decreased (P <0.01) after 14 d. In subjects treated with placebo first (group B, n = 6), all biochemical parameters were unchanged after placebo treatment, whereas the changes in free and total IGF-I were similar to those of group A after GH treatment. Combined clamp data from both groups A and B (n = 12) showed that 14-d GII treatment decreased overnight plasma insulin levels (P <0.02) and hepatic glucose appearance (P <0.05) and increased SI (P <0.01). Of note, the GH-induced changes in SI positively correlated with the changes in free IGF-I (r = 0.72, P <0.01). In conclusion, low-dose GH administration enhanced S I and suppressed endogenous peak GH release, and we hypothesize that these effects are the direct result of increased serum levels of free IGF-I.",
author = "Kevin Yuen and Jan Frystyk and Margot Umpleby and Linda Fryklund and David Dunger",
year = "2004",
month = "8",
doi = "10.1210/jc.2004-0300",
language = "English (US)",
volume = "89",
pages = "3956--3964",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak Growth Hormone (GH) release following short-term low-dose GH administration in young healthy adults

AU - Yuen, Kevin

AU - Frystyk, Jan

AU - Umpleby, Margot

AU - Fryklund, Linda

AU - Dunger, David

PY - 2004/8

Y1 - 2004/8

N2 - High-dose GH administration is commonly associated with impaired insulin sensitivity (SI) in humans. Paradoxically we have shown that low-dose GH (1.7 μg/kg·d) administration enhances β-cell function in young healthy adults. In the present double-blind, placebo-controlled, cross-over study, we explored the physiological effects of this low GH dose on glucose metabolism in 12 young healthy adults (seven males, 19-29 yr). At pretreatment and after each 14-d treatment block, overnight metabolic profiles were assessed followed by a hyperinsulinemic euglycemic clamp, whereas fasting blood samples were collected weekly. In subjects treated with GH first (group A, n = 6), GH treatment increased total IGF-I (P <0.05) and IGF binding protein-3 (P <0.01) after 7 d, but these levels subsequently returned to pretreatment levels after 14 d. In contrast, free IGF-I increased (P <0.05), and overnight GH pulse peak amplitude decreased (P <0.01) after 14 d. In subjects treated with placebo first (group B, n = 6), all biochemical parameters were unchanged after placebo treatment, whereas the changes in free and total IGF-I were similar to those of group A after GH treatment. Combined clamp data from both groups A and B (n = 12) showed that 14-d GII treatment decreased overnight plasma insulin levels (P <0.02) and hepatic glucose appearance (P <0.05) and increased SI (P <0.01). Of note, the GH-induced changes in SI positively correlated with the changes in free IGF-I (r = 0.72, P <0.01). In conclusion, low-dose GH administration enhanced S I and suppressed endogenous peak GH release, and we hypothesize that these effects are the direct result of increased serum levels of free IGF-I.

AB - High-dose GH administration is commonly associated with impaired insulin sensitivity (SI) in humans. Paradoxically we have shown that low-dose GH (1.7 μg/kg·d) administration enhances β-cell function in young healthy adults. In the present double-blind, placebo-controlled, cross-over study, we explored the physiological effects of this low GH dose on glucose metabolism in 12 young healthy adults (seven males, 19-29 yr). At pretreatment and after each 14-d treatment block, overnight metabolic profiles were assessed followed by a hyperinsulinemic euglycemic clamp, whereas fasting blood samples were collected weekly. In subjects treated with GH first (group A, n = 6), GH treatment increased total IGF-I (P <0.05) and IGF binding protein-3 (P <0.01) after 7 d, but these levels subsequently returned to pretreatment levels after 14 d. In contrast, free IGF-I increased (P <0.05), and overnight GH pulse peak amplitude decreased (P <0.01) after 14 d. In subjects treated with placebo first (group B, n = 6), all biochemical parameters were unchanged after placebo treatment, whereas the changes in free and total IGF-I were similar to those of group A after GH treatment. Combined clamp data from both groups A and B (n = 12) showed that 14-d GII treatment decreased overnight plasma insulin levels (P <0.02) and hepatic glucose appearance (P <0.05) and increased SI (P <0.01). Of note, the GH-induced changes in SI positively correlated with the changes in free IGF-I (r = 0.72, P <0.01). In conclusion, low-dose GH administration enhanced S I and suppressed endogenous peak GH release, and we hypothesize that these effects are the direct result of increased serum levels of free IGF-I.

UR - http://www.scopus.com/inward/record.url?scp=4043161588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043161588&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-0300

DO - 10.1210/jc.2004-0300

M3 - Article

C2 - 15292333

AN - SCOPUS:4043161588

VL - 89

SP - 3956

EP - 3964

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -